



Centers for Disease Control and Prevention

CDC 24/7: Saving Lives, Protecting People™

# VAERS


**Update: 01/29/2023**

# VAERS

Vaccine Adverse Event Reporting System

[www.vaers.hhs.gov](http://www.vaers.hhs.gov)

Number of COVID-19 vaccine doses administered in the United States as of January 4, 2023, by vaccine manufacturer



TOTAL MODERNA: 266,534,900 / 37.35%  
TOTAL PFIZER: 427,200,980/ 59.87%  
TOTAL J&J: 18,954,913 / 2.657%

TOTAL OTHER MANUFACTURERS: 854,905 /0.119%  
(160,666,080 MORE PFIZER SHOTS WERE ADMINISTERED  
THAN MODERNA: P= >M X 1.6027)

COMBINED TOTAL ALL MANUFACTURES: 713,545,698




# Vaccine Distribution

Johnson & Johnson  
2.6%

Moderna  
37%

Pfizer  
59.3%



- 266,534,900  
Moderna
- 427,200,980  
Pfizer
- 748,532 Unknown  
Manufacturer:
- 18,954,913  
Janssen

TOTAL MODERNA: 266,534,900 / 37.35%

TOTAL PFIZER: 427,200,980 / 59.87%

TOTAL J&J: 18,954,913 / 2.657%



# VAERS: 1/29/2023

AE=Adverse Events    D=Deaths  
M=Male    F= Female



## VAERS Data:

FOR THOSE WHO DID REPORT AN  
ADVERSE EVENT

**2.34%**

WERE DEATHS.

You had a **5X**

higher chance of dying if you  
had reported an adverse event  
than if you caught covid

Total figures, all  
manufactures, ages,  
and all doses. → **AE: 1,509,410**  
**D: 33,904**  
**Overall D%= 2.24%**

Total figures, for  
children/ 17yrs and  
younger. → **<17AE: 62,693**  
**<17D: 181**  
**<17 D%=0.288%**

Age (deaths/cases)	CFR (95% CI)
≤ 9 years (0/416)	0%
10 to 19 years (1/549)	0.18% (0.03 to 1.02%)
20 to 49 years (63/19790)	0.32% (0.25% to 0.41%)
50 to 59 years (130/10,008)	1.3% (1.1% to 1.5%)

THE COVID-19 CFR AVERAGE  
ACROSS AGES 0-60 WAS

**0.44%**



# Vaccine Adverse Events:

**Pfizer AE: 901,483**

**PFIZER D: 21,393**

**Lethality of Pfizer D/AE: 2.37%**

**(Pfizer D% is 1.27X > than Moderna D%)**

**Moderna AE: 512,032**


**MODERNA D: 9,538**

**Lethality of Moderna D/AE: 1.86%**

**J&J AE: 96,855**


**J&J D: 2,927**

**Lethality of J&J D/AE: 3.02%**




TOTAL VACCINE DOSES DISTRIBUTED  
IN THE UNITED STATES

712,690,798



TOTAL MODERNA: 266,534,900 / 37.35%  
TOTAL PFIZER: 427,200,980 / 59.87%  
TOTAL J&J: 18,954,913 / 2.657%





# LEAST DISTRIBUTED VACCINES:

**J&J AE: 96,855**

**J&J D: 2,927**

**Lethality: 3.02%**

**Unknown AE: 10,344**

**Unknown D: 219**

**Lethality: 2.11%**

**Novavax AE: 229**

**Novavax D: 0**

**Lethality: <0%**

(Lower decrease in deaths per dose compared to the decrease observed in Pfizer. I.E: Pfizer has more death than moderna but while the rate of death per dose mirrors moderna the percentage difference of 4th doses should have been less in moderna but remained >1%)

-----

**(JJD% is 1.106X higher than Pfizer D%) + (JJD% is 1.62X higher than Moderna D%)**


# What's the nation's progress on vaccinations? ⓘ

At least **262,908,216** people or **79%** of the population have received at least one dose.

Overall, **224,113,439** people or **68%** of the population are considered fully vaccinated.

Additionally, **108,806,974** people or **33%** of the population have received a booster dose.

## Percent of people receiving vaccines in the US



Sources: Centers for Disease Control and Prevention. [see more](#)

In the US, **953,826,425** doses have been distributed so far, with **70%** or **668,814,259** of the doses used.



# Dose Statistics



## **-----Pfizer-----**

**ALL AE 1 dose: 306,326**

**ALL AE 2 dose: 354,113**

**ALL AE 3 dose: 112,320**

**ALL AE 4 dose: 20,386**

**All AE Pfizer all doses: 901, 483**

### **Pfizer Deaths:**

**All D 1 dose: 6,815**

**All D 2 dose: 8,614**

**All D 3 dose: 2,468**

**All D 4 dose: 397**

**ALL D ALL doses: 21,393 pfizer**

## **--All AE Moderna --**

**All AE 1st dose: 240,070**

**All AE 2 dose: 126,878**

**ALL AE 3 dose: 62,868**

**ALL AE 4 dose: 14,015**

**All AE all doses: 512,032**

### **Moderna Deaths:**

**All D 1st dose: 3,802**

**All D 2nd dose: 3,907**

**All D 3 Dose: 1,124**

**All D 4th dose: 179**

**All D all doses: 9,538**

## **----All AE J&J ----**

**AE JJ dose 1: 57,626**

**AE JJ dose 2: 2,268**

**AE JJ dose 3: 400**

**AE JJ dose 4: 48**

**All D All doses: 2,927**

### **--Janssen Deaths--**

**D JJ dose 1: 1,682**

**D JJ dose 2: 92**

**D JJ Dose 3: 5**

**D JJ Dose 4: 0**

**All D All doses: 2,927**

# Dose Statistics



## What's the nation's progress on vaccinations?

At least **262,908,216** people or **79%** of the population have received at least one dose.

Overall, **224,113,439** people or **68%** of the population are considered fully vaccinated.

Additionally, **108,806,974** people or **33%** of the population have received a booster dose.

### Percent of people receiving vaccines in the US

■ One dose and incomplete ■ Two doses or equivalent ■ Three or more



ALL Manufacturers AE Dose 1: 606,417 [ 306,326P, 240,070M, 57,626J ]

ALL Manufacturers AE Dose 2: 486,767 [ 354,113P, 126,878M, 2,268J ]

ALL Manufacturers AE Dose 3: 176,857 [ 112,320P, 62,868M, 400J ]

ALL Manufacturers AE Dose 4: 34,783 [ 20,386P, 14,015M, 48J ]



ALL Manufacturers D Dose 1: 12,336

ALL Manufacturers D Dose 2: **12,661**

ALL Manufacturers D Dose 3: 3,606

ALL Manufacturers D Dose 4: 575

**Overall, the rate of Adverse reaction directly correlates to the rate of vaccination.**

**Although this trend is similar in the Vaccine Death Rate, there is a major discrepancy with the second dose, receiving a **higher** death rate than the 1st dose, despite 11% of the population receiving the second dose.**



**VAERS Totals -All Manufacturers:**

**Adverse Events : 1,509,410**

**Deaths : 33,904**

**Overall D/AE %= 2.34%**

**ALL Manufacturers D Dose 1: 12,336**

**ALL Manufacturers D Dose 2: 12,661**

**ALL Manufacturers D Dose 3: 3,606**

**ALL Manufacturers D Dose 4: 575**

**Pfizer Lethality D/AE: 2.37%**

**Janssen Lethality /AE: 3.02%**

**Moderna Lethality D/AE: 1.86%**

**Novavax/Unk. Lethality: 2.11%**

**= 2.34%**

**36.38%**

OF VAX DEATHS WERE  
FROM THE 1ST DOSE

**37.34%**

OF VAX DEATHS WERE  
FROM THE 2ND DOSE

**10.63%**

OF VAX DEATHS WERE  
FROM THE 3RD DOSE

**1.69%**

OF VAX DEATHS WERE FROM THE 4TH DOSE

# Gender Statistics ↓↓



**All Male AE: 496,799**

**All Male D: 18,277**

**Male Lethality Rate: 3.678%**



**ALL Female AE: 955,235**

**ALL Female D: 13,867**

**Female Lethality: 1.45%**



**Unknown gender AE: 57,376**

**Unknown gender D: 1,760**

**Unknown Gender  
Lethality Rate: 3.067%**



**\*(MD% is 2.53X higher than FD%)\***



# Gender and Disability

Women left  
permanently  
disabled

64%

Men left  
permanently  
disabled

34%

Women  
were  
**1.89X**

More likely than men to  
become Permanently  
Disabled following  
vaccination.

# OpenVAERS Red Box Summary:

1,505,275 Reports Through January 13, 2023 🇺🇸

source: OpenVAERS.com

33,746

DEATHS

189,384

HOSPITALIZATIONS

144,049

URGENT CARE

221,533

DOCTOR OFFICE VISITS

10,340

ANAPHYLAXIS

16,626

BELL'S PALSY

4,886

Miscarriages

18,261

Heart Attacks

26,221

Myocarditis/  
Pericarditis

62,253

Permanently  
Disabled

8,416

Thrombocytopenia/  
Low Platelet

36,027

Life Threatening

42,046

Severe Allergic  
Reaction

15,346

Shingles

# Birth/Pregnancy

**\*\*[Only congenital AE: Total: 6,196 & 510.38%]**

**Foetal chromosome abnormality 9/ 6,196 at .74%**

**Feotal Death: 55/ 6,196 at 4.35%**

**Foetal Disorder: 26/ 6,196 at 2.14%**

**Foetal Cardiac Arrest: 5/ 6,196at .41%**

**Foetal Cardiac Disorder: 16/ 6,196 at 1.32%**

**Foetal Growth restriction: 51/ 6,196 at 4.20%**

**Foetal abnormal heart rate: 43/6,196 at 3.54%**

**Inappropriate product administration: 30/6,196 at 2.47%**

**Mom exposed before pregnancy: 50/6,196 at 4.12%**

**Mom exposed during pregnancy: 230/ 6,196 at 18.95%**

**Mom exposed unknown time: 20/ 6,196at 1.65%**

**Paralysis: 4/ 6,196 at .33%**

**Premature: 24/ 6,196 at 1.89%**

**Stillbirth: 35/ 6,196 2.88%**

**Tachycardia: 16/ 6,196 1.32%**

**Delivery: 29/6,196 at 2.39%**

**Foetal hypokinesia: 15/6,196 at 1.24%**

**Congenital hydrocephalus: 6/6,196 at .49%**

**Congenital CNS anomaly: 9/6,196 at .74%**

**Congenial anomaly: 31/6,196 at 2.55%**

**Cerebrovascular accident: 20/6,196 at 1.65%**

**Cardiac disorder: 8/6,196 at .66%**

**C section: 13/6,196 at 1.07%**

**Bell's Palsy: 9/6,196 at .74%**

**Cytogenic abnormality: 6/6,196 at .49%**

**Atrial septal defect: 21/6,196 at 1.73%**

**Amniocentesis: 18/6,196 at 1.48%**

**Abortion spontaneous: 252/6,196 at 20.76%**

**Abortion induced: 23/6,196 at 1.89%**

**Myocarditis: 13/6,196 at 1.07%**



# Pfizer Reveals How Much They've Made From The COVID-19 Vaccine

Black Information Network

November 4, 2021



Pfizer reportedly made \$36 billion from COVID-19 vaccines this year. Heading into next year, the U.S. drugmaker expects to make \$29 billion from COVID-19 vaccines. Those projections could rise as Pfizer seeks to sign more deals with countries to produce vaccines. Overall, Pfizer hopes to produce four billion vaccines in 2022. Of those four billion doses, the drugmaker plans to allocate at least one billion vaccines for low and middle income countries.

# Pfizer Made \$36.8 Billion from Covid-19 Vaccine in 2021

By **Patricia Claus** February 9, 2022

## Pfizer has biggest-selling pharmaceuticals product in history

As a result of its groundbreaking technology, the pharma giant ended up with the largest selling pharmaceutical product in a single year ever in history.

Experts say that the firm, which is continuing to manufacture and promote its booster shots, will make another \$32 billion during this year. Still, the company admitted that its profits were down a bit from projections; with total revenues of \$98 to \$102 billion, the projected revenues had been *Axios* reports that Pfizer expects to rake in \$32 billion in vaccine sales in 2022 as well as \$22 billion just from the company's COVID pill Paxlovid.



# Pfizer to become \$100B behemoth next year thanks to COVID-19 drug and vaccine: analyst

By Angus Liu • Nov 23, 2021 10:35am

The COVID-19 pandemic is creating a \$100 billion pharma goliath.

Pfizer's revenue could reach \$101.3 billion in 2022, with major contributions coming from the company's BioNTech-partnered COVID vaccine and an antiviral therapeutic that has shown stellar clinical data, SVB Leerink analyst Geoffrey Porges projected in a Monday note to clients.

That level of revenue would be unheard of in the pharma industry. Johnson & Johnson, the world's largest biopharma company by revenue for years, [recorded](#) \$82.6 billion revenue in 2020. Pfizer's own revenue in 2018 clocked in at [\\$53.7 billion](#) before the separation of its consumer health franchise into a joint venture with GlaxoSmithKline in 2019.

Of the \$101.3 billion, oral COVID drug Paxlovid could contribute \$24.2 billion and COVID vaccine Comirnaty \$29.7 billion, Porges figured.





**F** PROFILE

# Ugur Sahin

**\$5.6B** Real Time Net Worth  
as of 1/29/23  
#458 in the world today



PHOTO BY FABIAN BIMMER/REUTERS/NEWSCOM



## About Ugur Sahin

- Uğur Şahin is CEO and cofounder of German biotech firm BioNTech, which partnered with Pfizer to produce the first Covid-19 vaccine approved in the US.
- Şahin led BioNTech to start on a vaccine for the coronavirus in early 2020; it partnered with Pfizer in March 2020 and got approval in December.





# Should covid-19 vaccines and drugs be “not for profit”?

BMJ 2022 ; 376 doi: <https://doi.org/10.1136/bmj.o755> (Published 30 March 2022)

Cite this as: BMJ 2022;376:o755

Article

Related content

Metrics

Responses

*Mohga Kamal-Yanni, freelance consultant in global health and access to medicines, policy and technical adviser to UNAIDS and the People's Vaccine Alliance<sup>1</sup>, Thomas Cueni, director general, International Federation of Pharmaceutical Manufacturers and Associations<sup>2</sup>*



Drug companies claim that high prices and high profits are essential for financing R&D. Yet covid-19 has clearly illustrated that public funding is the cornerstone of innovation. Governments played a key role in funding R&D and manufacturing: the UK public purse funded 97% of the Oxford-AstraZeneca vaccine,<sup>4</sup> the US government injected \$10bn into the NIH-Moderna vaccine,<sup>5</sup> and Pfizer and BioNTech received \$800m in R&D funding.<sup>6</sup> In 11 months, governments paid around \$100bn in funding the development of vaccines and therapeutics.<sup>7</sup>

